Abstract

The overall goals of this research are (a) to define the pathophysiology of cancer in man, and (b) to increase the cure rate. Our approach is to use a combination of laboratory studies and clinical trials correlated with our laboratory efforts in a multidisciplinary research effort in studies of: pharmacology of anticancer drugs and biological response modifiers, correlative laboratory studies of breast cancer and non-hodgkin's lymphomas, and to develop in vitro models for biological therapy, and for analysis of drug resistance and of the sensitivity of clonogenic human tumor cells to drugs, biologicals and hormones, including an analysis of glucocorticoid receptor expression. These laboratory studies will be linked prospectively to correlative clinical trials of cancer therapy.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA017094-14
Application #
3092741
Study Section
Cancer Therapeutics Program Project Review Committee (CTR)
Project Start
1978-06-01
Project End
1992-11-30
Budget Start
1988-12-01
Budget End
1989-11-30
Support Year
14
Fiscal Year
1989
Total Cost
Indirect Cost

  Institution

Name
University of Arizona
Department
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722

  Publications

Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797

Showing the most recent 10 out of 314 publications